ClinicalTrials.gg
CompletedNCT01247194Updated Feb 3, 2012

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

A Phase 1 interventional study of PPI-461 and Placebo in Chronic Genotype 1 Hepatitis C Virus Infection, sponsored by Presidio Pharmaceuticals, Inc.. Completed at 11 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Presidio Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Hepatitis C with a site in Denmark — 1 open to participants now, 1 under way, none of them phase 3. Hepatitis C · Denmark.

Enrollment
12th of 12
24 · median 455
Started
2010
with 3 others
Phase 1
2 of 17
none open now
Registered
5th of 17
by date
Lead sponsor
1 of 17
Presidio Pharmaceuticals, Inc.

Among the 17 studies in Hepatitis C with a site in Denmark, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2010, is one of 2 in phase 1, and was the 5th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 17 studies in Hepatitis C with a site in Denmark is open now. Recruiting first, the newest first:

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Hepatitis C with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.

03

Conditions studied

  • Chronic Genotype 1 Hepatitis C Virus Infection

Browse trials for

Keywords

  • hepatitis C
  • NS5A
  • HCV RNA
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria:

  • Male or female, between 18 and 65 years of age (female patients must be surgically sterile or 2 years and are required to take a pregnancy test)
  • (BMI) 18 - 32 kg/m2
  • Chronically infected with genotype-1 virus
  • Serum HCV RNA > 5 log10 IU/mL
  • No previous treatment with interferon, peginterferon, ribavirin or any HCV antiviral agents
  • No history of signs or symptoms of decompensated liver disease
  • No known history of cirrhosis
  • No co-infection with , -1, HIV-2
  • No history of any medical condition that may interfere with absorption, distribution or elimination of study drug or with the clinical and laboratory assessments in this study
  • No history of alcohol abuse, or illicit drug use within 2 years prior to Screen, or enrollment in a methadone maintenance program (unless he/she has been enrolled in the methadone program for at least 3 months with good compliance, stable psychosocial circumstances, and no known current risks for recidivism)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Cohort A

    PPI-461 50 mg or placebo

    Drug: PPI-461 · Drug: Placebo

  • Active comparator
    Cohort B

    PPI-461 100 mg or placebo

    Drug: PPI-461 · Drug: Placebo

  • Active comparator
    Cohort C

    PPI-461 200 mg or placebo

    Drug: PPI-461 · Drug: Placebo

Interventions

  • DrugPPI-461

    capsule, oral, once daily for 3 days

  • DrugPlacebo

    capsules, oral, once daily for 3 days

06

What researchers measure

Primary outcomes

  1. Safety and tolerability, as measured by clinical adverse events and laboratory assessments

    Time frame: up to Study Day 16 (14 days after the last PPI-461 dose)

  2. Antiviral effects of PPI-461, as measured by HCV RNA levels

    Time frame: Up to Study Day 16 (14 days after the last PPI-461 dose)

  3. PPI-461 pharmacokinetics as measured by plasma PPI-461 concentrations

    Time frame: Up to Study Day 10 (8 days after the last PPI-461 dose)

07

Study locations

11 sites
  • Local Institution
    Sacramento, California 95817, United States
  • Local institution
    San Francisco, California 94115, United States
  • Local institution
    Aarhus, Denmark
  • Local institution
    Copenhagen, Denmark
  • Local institution
    Herlev, Denmark
  • Local institution
    Hvidovre, Denmark
  • Local institution
    Kolding, Denmark
  • Local institution
    Odense, Denmark
  • Local institution
    London, NW3 2QG, United Kingdom
  • Local institution
    London, SE5 9RS, United Kingdom
  • Local institution
    London, W2 1NY, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2010
First posted
Nov 24, 2010
Start
Oct 2010
Primary completionActual
May 2011
CompletionActual
Jun 2011
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01247194
Lead sponsor
Presidio Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 24, 2010
Start date
Oct 2010
Primary completion
May 2011
Completion
Jun 2011
Last update
Feb 3, 2012

Study contacts

Nathaniel Brown, M.D.
study director · Presidio Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion